CONTEXT AND OBJECTIVE: We propose to systematically review the available evidence to evaluate if patients with immune mediated inflammatory diseases under pharmacological treatment with immunosuppressants, immunobiologics, Disease-Modifying Anti-Rheumatic Drugs (DMARD) or targeted synthetic DMARDs have better or worse outcomes when infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This study is a protocol for our rapid living systematic review. METHODS: Protocol for a rapid living systematic review methodology following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidance. To conduct the rapid systematic review, we will employ abbreviated systematic review methods, including: not performing independent screens of abstracts and not searching grey literature. As this will be a living review, it will be continuously updated.

中文翻译：

---

COVID-19和正在接受药物治疗的免疫介导的炎症性疾病患者：快速生存系统评估的协议

内容与目的：我们建议系统地审查现有证据，以评估接受免疫抑制剂，免疫生物学药，抗病抗风湿药（DMARD）或靶向合成DMARD药物治疗的免疫介导炎性疾病患者在感染时是否有更好或更差的结果由严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）引起。这项研究是我们快速生活系统评价的方案。方法：遵循“系统评价和荟萃分析方案的首选报告项目”（PRISMA-P）指南的快速生活系统评价方法的方案。为了进行快速的系统评价，我们将采用简化的系统评价方法，包括：不执行独立的摘要筛选和不检索灰色文献。